Novo's Tresiba deadline in Germany looms; Scots back reimbursement for Sanofi's Toujeo; Reddy's teams up with Hatchtech on anti-lice med;

> Novo Nordisk ($NVO) said its long-acting basal insulin Tresiba would no longer be available in Germany as of next month; the Danish drugmaker had previously announced its intention to withdraw the product in a pricing dispute with German insurers. Report

> The Scottish Medicines Consortium gave its blessing to Sanofi's ($SNY) new basal insulin Toujeo, clearing the way for its routine use by the country's health service. Report

> Dr. Reddy's Laboratories ($RDY) inked a deal with the Australian drugmaker Hatchtech to develop and sell a prescription head lice product, Xeglyze, in a variety of countries, including the U.S. Report

> India's Sun Pharmaceutical saw shares rise on hopes for a periodic paralysis drug, Keveyis, which its U.S. unit Taro Pharmaceutical is preparing to launch. Report

> More pharma companies are jumping on the wearables bandwagon, with plans to distribute Fitbits and other devices to clinical trial participants and patients. Report

And Finally... A vaccine billionaire snapped up a former maharaja's Mumbai mansion for 7.5 billion rupees ($113 million) in the biggest-ever residential deal in India. Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.